Company Description
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care.
The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream.
Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis.
The company is also developing EB612 as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism.
In addition, it is developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome.
The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
| Country | Israel |
| Founded | 2010 |
| IPO Date | Jun 28, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Miranda Toledano |
Contact Details
Address: Kiryat Hadassah Minrav Building, Fifth Floor Jerusalem, 9112002 Israel | |
| Phone | 972 2 532 7151 |
| Website | enterabio.com |
Stock Details
| Ticker Symbol | ENTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001638097 |
| CUSIP Number | M40527109 |
| ISIN Number | IL0011429839 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Miranda J. Toledano M.B.A. | Chief Executive Officer and Director |
| Dana Yaacov-Garbeli CPA | Chief Financial Officer |
| Dr. Hillel Galitzer M.B.A., Ph.D. | Chief Operating Officer |
| Dr. Gregory Burshtein Ph.D. | Chief of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 20, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 9, 2024 | 8-K | Current Report |
| Aug 2, 2024 | 8-K | Current Report |
| Jun 20, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 20, 2024 | ARS | Filing |
| Jun 20, 2024 | DEF 14A | Other definitive proxy statements |
| May 29, 2024 | PRE 14A | Other preliminary proxy statements |
| May 10, 2024 | 10-Q | Quarterly Report |